Nuohui Health (06606) announced that for the six months ended June 30, 2022, the group's total revenue is expected to range from 217.1 million yuan to 231.6 million yuan (the same below), an increase of 394.5% over the same period last year. 427.6%. Gross profit is expected to range from 182.2 million yuan to 191.1 million yuan, an increase of 637.7% to 673.7% over the same period last year. The increase in total revenue and gross profit was mainly due to the increase in revenue and gross profit of the products (namely Chang Weiqing and Pupu tube), as well as the launch of the new product claustrophobia in January 2022.
During the period, gross profit margin is expected to range from 78.7% to 88.0%, an upward trend from about 56.2% in the same period last year. The increase in the overall gross profit margin is mainly due to the increase in the gross profit margin of Chang Weiqing and Pupu pipe, as well as the considerable gross profit margin of the claustrophobia.
